NUZ – Neurizon Therapeutics Limited
14th January 2019 – Perth, Australia: PharmAust Limited (ASX: PAA), a clinical stage oncology company that is engaged in collaboration with the Olivia Newton-John Cancer Research Institute (ONJCRI), is pleased to announce important findings confirming anti-cancer activity of monepantel’s major metabolite, monepantel sulfone.
The human cancer cell lines tested were representative of cancers that PharmAust is currently studying for treatment in its upcoming Phase II trial in humans. Importantly, the ONJCRI researchers also demonstrated that, like monepantel, the metabolite has relatively little toxicity upon non-cancer human cells.
